Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia

Luxeptinib (CG-806) simultaneously targets FLT3 and select other kinase pathways operative in myeloid malignancies. We investigated the range of kinases it inhibits, its cytotoxicity landscape ex vivo with acute myeloid leukemia (AML) patient samples, and its efficacy in xenograft models. Luxeptinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Rice, William G., Howell, Stephen B., Zhang, Hongying, Rastgoo, Nasrin, Local, Andrea, Kurtz, Stephen E., Lo, Pierrette, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256809/
https://www.ncbi.nlm.nih.gov/pubmed/35499387
http://dx.doi.org/10.1158/1535-7163.MCT-21-0832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256809/
https://www.ncbi.nlm.nih.gov/pubmed/35499387
http://dx.doi.org/10.1158/1535-7163.MCT-21-0832

Ejemplares similares